Indivior Pharmaceuticals Analyst Price Targets - Benzinga

Indivior Pharmaceuticals Inc

INDVNASDAQ

Trade with Public

Trade with Public

$34.47

-0.86-2.43%

最終更新: Oct 23, 4:00 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

© 2026 Benzinga | All Rights Reserved

Indivior Pharmaceuticals Analyst Price Targets - Benzinga

Indivior Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Indivior Pharmaceuticals (INDV).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$37Upside to Avg. PT+7.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 5, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$46→$43
Jun 18, 2026	Barclays	Glen Santangelo	Initiate	Overweight	$46
Jan 12, 2026	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$35→$48
Oct 31, 2025	Piper Sandler	David Amsellem	PT Raise	Overweight	$27→$41
Oct 30, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$28→$35
Aug 27, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$27→$34
Aug 6, 2025	HC Wainwright & Co.	Brandon Folkes	Initiate	Buy	$28
Jul 22, 2025	Jefferies	Dennis Ding	Assumes	Buy	$20
Jun 30, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$15→$22
Mar 6, 2025	Piper Sandler	David Amsellem	PT Cut	Overweight	$16→$13
Oct 25, 2024	Piper Sandler	David Amsellem	PT Raise	Overweight	$15→$16
Oct 11, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$20→$16
Oct 11, 2024	Piper Sandler	David Amsellem	PT Cut	Overweight	$22→$15
Sep 13, 2024	Piper Sandler	David Amsellem	Maintained	Overweight	$22
Jul 23, 2024	Piper Sandler	David Amsellem	Initiate	Overweight	$22
Jul 10, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$37→$24
Apr 3, 2024	Craig-Hallum	Chase Knickerbocker	Initiate	Buy	$37

Analyst Ratings News

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and lowers the price target from $46 to $43.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight rating and announces Price Target of $46.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $35 to $48.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Indivior, Raises Price Target to $41

Piper Sandler analyst David Amsellem reiterates Indivior (NASDAQ:INDV) with a Overweight and raises the price target from $27 to $41.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $35

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $28 to $35.

Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on Indivior, Raises Price Target to $34

Craig-Hallum analyst Chase Knickerbocker maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $27 to $34.

Benzinga Newsdesk